Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 20, Pages 5055
Publisher
MDPI AG
Online
2019-10-11
DOI
10.3390/ijms20205055
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Increased production and reduced urinary buffering of acid in uric acid stone formers is ameliorated by pioglitazone
- (2019) Naim M. Maalouf et al. KIDNEY INTERNATIONAL
- Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
- (2019) Koutaro Yokote et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis
- (2019) Akira Honda et al. HEPATOLOGY
- Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications
- (2019) Agha Zeeshan Mirza et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Exploiting vulnerabilities of cancer by targeting nuclear receptors of stromal cells in tumor microenvironment
- (2019) Hong Sheng Cheng et al. Molecular Cancer
- A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High Risk Current and Former Smokers
- (2019) Robert L. Keith et al. Cancer Prevention Research
- New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
- (2019) Upendra Kaul et al. Cardiovascular Diabetology
- 17-OR: Efficacy and Safety of Chiglitazar, a Novel PPARα/γ/d Pan-Agonist, in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial (CMAP)
- (2019) LINONG JI et al. DIABETES
- Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial
- (2019) Jeroen V. Koomen et al. DIABETES OBESITY & METABOLISM
- Effect of Thiazolidinediones on Renal Outcomes in Diabetic Patients with Microalbuminuria or Macroalbuminuria-A Systematic Review and Meta-analysis
- (2018) YAO QIN et al. DIABETES
- Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
- (2018) Eiichi Araki et al. DIABETES CARE
- Molecular actions of PPARα in lipid metabolism and inflammation
- (2018) Nadia Bougarne et al. ENDOCRINE REVIEWS
- Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
- (2018) Hidenori Arai et al. Journal of Atherosclerosis and Thrombosis
- Pioglitazone Therapy of PAX8-PPARγ Fusion Protein Thyroid Carcinoma
- (2018) Thomas J Giordano et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
- (2018) Shun Ishibashi et al. Journal of Clinical Lipidology
- A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
- (2018) Christophe Corpechot et al. NEW ENGLAND JOURNAL OF MEDICINE
- ROS release by PPARβ/δ-null fibroblasts reduces tumor load through epithelial antioxidant response
- (2018) Eddie Han Pin Tan et al. ONCOGENE
- The peroxisome proliferator-activated receptor agonist pioglitazone and 5-lipoxygenase inhibitor zileuton have no effect on lung inflammation in healthy volunteers by positron emission tomography in a single-blind placebo-controlled cohort study
- (2018) Delphine L. Chen et al. PLoS One
- Protective effects of Withania somnifera extract in SOD1G93A mouse model of amyotrophic lateral sclerosis
- (2018) Kallol Dutta et al. EXPERIMENTAL NEUROLOGY
- Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with sepsis: a randomized clinical trial
- (2018) Jennifer M. Kaplan et al. INTENSIVE CARE MEDICINE
- The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
- (2018) Fan Hong et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Testing the PPAR hypothesis of tobacco use disorder in humans: A randomized trial of the impact of gemfibrozil (a partial PPARα agonist) in smokers
- (2018) Marie N. S. Gendy et al. PLoS One
- Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder
- (2018) Jennifer R. Schroeder et al. PSYCHOPHARMACOLOGY
- Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome
- (2018) Simona Mihai et al. Journal of Immunology Research
- Increased Fibro-Adipogenic Progenitors and Intramyocellular Lipid Accumulation in Obesity-Related Skeletal Muscle Dysfunction
- (2018) Guanghong Jia et al. DIABETES
- Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial
- (2018) Bancha Satirapoj et al. PLoS One
- A pilot dose finding study of pioglitazone in autistic children
- (2018) Lucia Capano et al. Molecular Autism
- Emerging Therapeutic Role of PPAR–α in Cognition and Emotions
- (2018) Khalin E. Nisbett et al. Frontiers in Pharmacology
- Double-blind, placebo-controlled trial of pioglitazone for bipolar depression
- (2018) Awais Aftab et al. JOURNAL OF AFFECTIVE DISORDERS
- Rationale for an adjunctive therapy with fenofibrate in pharmacoresistant nocturnal frontal lobe epilepsy
- (2017) Monica Puligheddu et al. EPILEPSIA
- Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome
- (2017) Chek Kun Tan et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma
- (2017) Maryann Kaler et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
- (2017) Yong-ho Lee et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial
- (2017) Charlotte Koopal et al. JOURNAL OF LIPID RESEARCH
- Safety and tolerability of adjunctive rosiglitazone treatment for children with uncomplicated malaria
- (2017) Rosauro Varo et al. MALARIA JOURNAL
- Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential
- (2017) Jermaine D. Jones et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial
- (2017) Ruth Bolier et al. Trials
- Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy
- (2017) Qian Gou et al. Oncotarget
- Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis
- (2017) Wen Wang et al. Scientific Reports
- Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
- (2017) Olga Vaccaro et al. Lancet Diabetes & Endocrinology
- A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying [18F]FDG-PET for Evaluation of Metabolic Therapy with Rosiglitazone XR in Mild to Moderate Alzheimer's Disease
- (2017) Sofia Tzimopoulou et al. JOURNAL OF ALZHEIMERS DISEASE
- Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist, CS-7017, in patients with advanced malignancies.
- (2017) M. J. Pishvaian et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized, open-label phase II study of efatutazone in combination with FOLFIRI as second-line therapy for metastatic colorectal cancer (mCRC).
- (2017) John Marshall et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- A pilot study of MBX-8025 in the treatment of homozygous familial hypercholesterolemia (HoFH)
- (2016) D. Gaudet et al. ATHEROSCLEROSIS
- Peroxisome proliferator-activated receptors (PPAR) downregulate the expression of pro-inflammatory molecules in an experimental model of myocardial infarction
- (2016) María de la Luz Ibarra-Lara et al. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
- Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study
- (2016) Philippe Rousselot et al. CANCER
- Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial
- (2016) Yaron Arbel et al. Cardiovascular Diabetology
- Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World
- (2016) Mehmet Sayiner et al. Clinics in Liver Disease
- Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial
- (2016) A. O. Stirban et al. DIABETES OBESITY & METABOLISM
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes
- (2016) Suetonia C. Palmer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pioglitazone as a novel therapeutic approach in chronic granulomatous disease
- (2016) Maddalena Migliavacca et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients
- (2016) Leonardo Calza et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pioglitazone Therapy Increases Insulin-Stimulated Release ofd-Chiro-Inositol-Containing Inositolphosphoglycan Mediator in Women with Polycystic Ovary Syndrome
- (2016) Anshu Gupta et al. Metabolic Syndrome and Related Disorders
- Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
- (2016) Walter N. Kernan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users
- (2016) Jermaine D. Jones et al. PHYSIOLOGY & BEHAVIOR
- Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial
- (2016) J. R. Anderson et al. PLoS One
- Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ
- (2016) Nguan Soon Tan et al. PROGRESS IN LIPID RESEARCH
- Does enhanced insulin sensitivity improve sleep measures in patients with obstructive sleep apnea: a randomized, placebo-controlled pilot study
- (2016) Alice Liu et al. SLEEP MEDICINE
- Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes
- (2015) A. C. Cheung et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effects of the dual peroxisome proliferator–activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes
- (2015) Erland Erdmann et al. AMERICAN HEART JOURNAL
- Pioglitazone Increases Circulating MicroRNA-24 With Decrease in Coronary Neointimal Hyperplasia in Type 2 Diabetic Patients – Optical Coherence Tomography Analysis –
- (2015) Soon Jun Hong et al. CIRCULATION JOURNAL
- Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation
- (2015) Michael P. Dubé et al. CLINICAL INFECTIOUS DISEASES
- Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials
- (2015) R. R. Henry et al. DIABETES OBESITY & METABOLISM
- Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension
- (2015) S.-M. Jin et al. DIABETES OBESITY & METABOLISM
- Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2015) Silvio E. Inzucchi et al. DIABETOLOGIA
- A randomized controlled trial of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone for clomifene-citrate-resistant polycystic ovary syndrome
- (2015) Waleed El-khayat et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
- Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study
- (2015) Ryota Tanaka et al. Journal of Atherosclerosis and Thrombosis
- PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis
- (2015) Sven Francque et al. JOURNAL OF HEPATOLOGY
- Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial
- (2015) C. Hart et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
- (2015) LANCET NEUROLOGY
- Pioglitazone treatment enhances the sympathetic nervous system response to oral carbohydrate load in obese individuals with metabolic syndrome
- (2015) Nora E. Straznicky et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence
- (2015) Kenneth A. Perkins et al. NICOTINE & TOBACCO RESEARCH
- A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism
- (2015) Ali Ghaleiha et al. PSYCHIATRY RESEARCH
- Adjuvant pioglitazone for unremitted depression: Clinical correlates of treatment response
- (2015) Kathleen Watson Lin et al. PSYCHIATRY RESEARCH
- Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis
- (2015) Alla Y. Grigorian et al. Clinics and Research in Hepatology and Gastroenterology
- Autoimmune encephalitis in humans: how closely does it reflect multiple sclerosis ?
- (2015) Romana Höftberger et al. Acta Neuropathologica Communications
- PPARβ activation restores the high glucose-induced impairment of insulin signalling in endothelial cells
- (2014) A M Quintela et al. BRITISH JOURNAL OF PHARMACOLOGY
- PPAR-γ Agonism as a Modulator of Mood: Proof-of-Concept for Pioglitazone in Bipolar Depression
- (2014) David E. Kemp et al. CNS DRUGS
- Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
- (2014) Michael C. d’Emden et al. DIABETOLOGIA
- New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease
- (2014) Amirhossein Sahebkar et al. EXPERT OPINION ON PHARMACOTHERAPY
- PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43
- (2014) Archi Joardar et al. HUMAN MOLECULAR GENETICS
- Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus
- (2014) A. Michael Lincoff et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effectofrosiglitazoneonserum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: Results froma pilot phase 2 study
- (2014) F. Bogazzi et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin
- (2014) Ching-Sheng Hsu et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Bezafibrate in skeletal muscle fatty acid oxidation disorders: A randomized clinical trial
- (2014) M. C. Orngreen et al. NEUROLOGY
- The Effects of Medical Management on the Progression of Diabetic Retinopathy in Persons with Type 2 Diabetes
- (2014) Emily Y. Chew et al. OPHTHALMOLOGY
- Efficacy and Safety of Lobeglitazone Monotherapy in Patients with Type 2 Diabetes Mellitus over 24-Weeks: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial
- (2014) Sin Gon Kim et al. PLoS One
- Pioglitazone Improves Fat Distribution, the Adipokine Profile and Hepatic Insulin Sensitivity in Non-Diabetic End-Stage Renal Disease Subjects on Maintenance Dialysis: A Randomized Cross-Over Pilot Study
- (2014) Anne Zanchi et al. PLoS One
- Carcinogenicity study of CKD-501, a novel dual peroxisome proliferator-activated receptors α and γ agonist, following oral administration to Sprague Dawley rats for 94–101weeks
- (2014) Hee Su Lee et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study
- (2014) Luis Ruilope et al. BMC Nephrology
- Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic Burkitt lymphoma in Malawi; an open-label, single-arm, phase 2 study (ISRCTN34303497)
- (2013) Elizabeth Molyneux et al. BRITISH JOURNAL OF HAEMATOLOGY
- Effects of Bezafibrate Treatment in a Patient and a Carrier With Mutations in the PNPLA2 Gene, Causing Neutral Lipid Storage Disease With Myopathy
- (2013) Tineke van de Weijer et al. CIRCULATION RESEARCH
- Peroxisome Proliferator-Activated Receptor (PPAR) Agonists as Promising New Medications for Drug Addiction: Preclinical Evidence
- (2013) Bernard Le Foll et al. CURRENT DRUG TARGETS
- Therapeutic Prospects of PPARs in Psychiatric Disorders: A Comprehensive Review
- (2013) Benjamin Rolland et al. CURRENT DRUG TARGETS
- Cardiovascular disease in lupus
- (2013) Jason S. Knight et al. CURRENT OPINION IN RHEUMATOLOGY
- Dual Peroxisome Proliferator-Activated Receptor / Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
- (2013) B. Cariou et al. DIABETES CARE
- A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)
- (2013) Rajendrakumar H. Jani et al. Diabetes Technology & Therapeutics
- CKD-501, a novel selective PPARγ agonist, shows no carcinogenic potential in ICR mice following oral administration for 104 weeks
- (2013) Kyoung-Sik Moon et al. JOURNAL OF APPLIED TOXICOLOGY
- Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial
- (2013) R. C. Smallridge et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension
- (2013) Kimberly Gilbert et al. JOURNAL OF HYPERTENSION
- Combination Therapy with Metformin and Fenofibrate for Insulin Resistance in Obesity
- (2013) X-M Li et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- PPARγ signaling and metabolism: the good, the bad and the future
- (2013) Maryam Ahmadian et al. NATURE MEDICINE
- A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer
- (2013) Nathan J. Robison et al. PEDIATRIC BLOOD & CANCER
- Vildagliptin and Pioglitazone in Patients With Impaired Glucose Tolerance After Kidney Transplantation
- (2013) Johannes Werzowa et al. TRANSPLANTATION
- Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial
- (2013) Michelle J Ormseth et al. ARTHRITIS RESEARCH & THERAPY
- PPAR-α as a Key Nutritional and Environmental Sensor for Metabolic Adaptation
- (2013) Alejandra V. Contreras et al. Advances in Nutrition
- The Peroxisome Proliferator Activated Receptor‐γ Pioglitazone Improves Vascular Function and Decreases Disease Activity in Patients With Rheumatoid Arthritis
- (2013) Wendy Marder et al. Journal of the American Heart Association
- Effects of Thiazolidinediones on Polycystic Ovary Syndrome: a Meta-analysis of Randomized Placebo-Controlled Trials
- (2012) Qiang Du et al. ADVANCES IN THERAPY
- Lipid Effects of Peroxisome Proliferator-Activated Receptor-Δ Agonist GW501516 in Subjects With Low High-Density Lipoprotein Cholesterol
- (2012) Eric J. Olson et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Role of the PPAR-α agonist fenofibrate in severe pediatric burn
- (2012) Itoro E. Elijah et al. BURNS
- Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
- (2012) Alexander Tenenbaum et al. Cardiovascular Diabetology
- Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy
- (2012) Xiao Feng HAN et al. Journal of Digestive Diseases
- Pioglitazone Adjunctive Therapy for Moderate-to-Severe Major Depressive Disorder: Randomized Double-Blind Placebo-Controlled Trial
- (2012) Khatereh Sepanjnia et al. NEUROPSYCHOPHARMACOLOGY
- Pioglitazone Decreases Hepatitis C Viral Load in Overweight, Treatment Naïve, Genotype 4 Infected-Patients: A Pilot Study
- (2012) Mario Chojkier et al. PLoS One
- A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis
- (2012) Luc Dupuis et al. PLoS One
- Bezafibrate for X-Linked Adrenoleukodystrophy
- (2012) Marc Engelen et al. PLoS One
- Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: A randomized double-blind study
- (2012) Robert C. Smith et al. SCHIZOPHRENIA RESEARCH
- Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus
- (2012) S. Suryadevara et al. THROMBOSIS AND HAEMOSTASIS
- PPARs at the crossroads of lipid signaling and inflammation
- (2012) Walter Wahli et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Peroxisome Proliferator–Activated Receptor‐α Agonism With Fenofibrate Does Not Suppress Inflammatory Responses to Evoked Endotoxemia
- (2012) Claire K. Mulvey et al. Journal of the American Heart Association
- Rosiglitazone decreases fasting plasma peptide YY3–36 in type 2 diabetic women: a possible role in weight gain?
- (2011) Zehra Berberoglu et al. ACTA DIABETOLOGICA
- Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis
- (2011) Meng Lee et al. ATHEROSCLEROSIS
- Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia
- (2011) Yun-Jung Choi et al. ATHEROSCLEROSIS
- Adiponectin Is Required for PPARγ-Mediated Improvement of Endothelial Function in Diabetic Mice
- (2011) Wing Tak Wong et al. Cell Metabolism
- Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: Result from a crossover study
- (2011) Masa-aki Kawashiri et al. CLINICA CHIMICA ACTA
- Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies
- (2011) C. Harrington et al. Current Alzheimer Research
- Effects of the New Dual PPAR / Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
- (2011) B. Cariou et al. DIABETES CARE
- 9059 POSTER Phase 1b Study of Oral PPAR-gamma Agonist Efatutazone (CS-7017) in Combination With Carboplatin and Paclitaxel in Chemotherapy-Naive Korean Patients With Metastatic or Unresectable Locally Advanced Non-Small Cell Lung Cancer
- (2011) K. Park et al. EUROPEAN JOURNAL OF CANCER
- Treatment of Androgen Excess in Adolescent Girls: Ethinylestradiol-CyproteroneacetateVersusLow-Dose Pioglitazone-Flutamide-Metformin
- (2011) Lourdes Ibáñez et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Mechanism of Action of a Peroxisome Proliferator-Activated Receptor (PPAR)-δ Agonist on Lipoprotein Metabolism in Dyslipidemic Subjects with Central Obesity
- (2011) Esther M. M. Ooi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Combination of Niacin and Fenofibrate with Lifestyle Changes Improves Dyslipidemia and Hypoadiponectinemia in HIV Patients on Antiretroviral Therapy: Results of “Heart Positive,” a Randomized, Controlled Trial
- (2011) Ashok Balasubramanyam et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin
- (2011) Harold E. Bays et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Drospirenone/Ethinyl EstradiolVersusRosiglitazone Treatment in Overweight Adolescents with Polycystic Ovary Syndrome: Comparison of Metabolic, Hormonal, and Cardiovascular Risk Factors
- (2011) Hala Tfayli et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pharmacokinetic-Pharmacodynamic Assessment of the Interrelationships Between Tesaglitazar Exposure and Renal Function in Patients With Type 2 Diabetes Mellitus
- (2011) Bengt Hamrén et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Pioglitazone improves the cardiovascular profile in patients with uncomplicated systemic lupus erythematosus: a double-blind randomized clinical trial
- (2011) JG Juárez-Rojas et al. LUPUS
- Rosiglitazone does not improve vascular function in subjects with chronic kidney disease
- (2011) D. T. Chan et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Correction: Targeting Vascular NADPH Oxidase 1 Blocks Tumor Angiogenesis through a PPARα Mediated Mechanism
- (2011) Sarah Garrido-Urbani et al. PLoS One
- The Era of Direct-Acting Antivirals Has Begun: The Beginning of the End for HCV?
- (2011) Marie-Louise Vachon et al. SEMINARS IN LIVER DISEASE
- Rosiglitazone Add-On in Treatment of Depressed Patients with Insulin Resistance: a Pilot Study
- (2011) Natalie L. Rasgon et al. TheScientificWorldJOURNAL
- Pioglitazone Attenuates Atherosclerotic Plaque Inflammation in Patients With Impaired Glucose Tolerance or Diabetes
- (2011) Minori Mizoguchi et al. JACC-Cardiovascular Imaging
- PPARγ Agonist Beyond Glucose Lowering Effect
- (2011) Akira Sugawara et al. KOREAN JOURNAL OF INTERNAL MEDICINE
- Carotid Intima Media Thickness, Inflammatory Markers, and Endothelial Activation Markers in HIV Patients with Lipoatrophy Increased at 48 Weeks Regardless of Use of Rosiglitazone or Placebo
- (2010) Marisa Tungsiripat et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid
- (2010) C. Levy et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Topical Rosiglitazone Treatment Improves Ulcerative Colitis by Restoring Peroxisome Proliferator-Activated Receptor-γ Activity
- (2010) Gitte Pedersen et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Prevention of Cardiovascular Disease Utilizing Fibrates-A Pooled Meta-analysis
- (2010) Rohit Seth Loomba et al. AMERICAN JOURNAL OF THERAPEUTICS
- Rosiglitazone Revisited
- (2010) Steven E. Nissen et al. ARCHIVES OF INTERNAL MEDICINE
- A Randomized Pilot Clinical Trial of the Safety of Pioglitazone in Treatment of Patients With Alzheimer Disease
- (2010) David S. Geldmacher et al. ARCHIVES OF NEUROLOGY
- Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial
- (2010) Olivier F. Bertrand et al. ATHEROSCLEROSIS
- The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials
- (2010) Siddharth H Sheth et al. BMC INFECTIOUS DISEASES
- Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML)
- (2010) Jim A. Murray et al. BRITISH JOURNAL OF HAEMATOLOGY
- Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis
- (2010) X-J. Li et al. CLINICAL ENDOCRINOLOGY
- Proof of concept study: does fenofibrate have a role in sleep apnoea syndrome?
- (2010) Eric Bruckert et al. CURRENT MEDICAL RESEARCH AND OPINION
- Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2010) Michael Gold et al. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
- Effects of high dose aleglitazar on renal function in patients with type 2 diabetes
- (2010) Matthias Herz et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis
- (2010) Eric Bruckert et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease
- (2010) Elisa Fabbrini et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics
- (2010) Diane Brisson et al. Pharmacogenetics and Genomics
- Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review
- (2009) Samuel Abourbih et al. AMERICAN JOURNAL OF MEDICINE
- Efficacy and Safety of Combination Acitretin and Pioglitazone Therapy in Patients With Moderate to Severe Chronic Plaque-Type Psoriasis
- (2009) Rajan Mittal et al. ARCHIVES OF DERMATOLOGY
- Use of Peroxisome Proliferator‐Activated Receptor γ Agonists as Adjunctive Treatment forPlasmodium falciparumMalaria: A Randomized, Double‐Blind, Placebo‐Controlled Trial
- (2009) Andrea K. Boggild et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes
- (2009) Cindy J. Rubin et al. Diabetes & Vascular Disease Research
- Coadministration of muraglitazar plus glyburide: Improvement of glycaemic and lipid profiles in patients with type 2 diabetes
- (2009) Cindy J. Rubin et al. Diabetes & Vascular Disease Research
- Vascular insulin resistance in prehypertensive rats: Role of PI3-kinase/Akt/eNOS signaling
- (2009) Rong Li et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- How safe is the use of thiazolidinediones in clinical practice?
- (2009) CV Rizos et al. Expert Opinion On Drug Safety
- Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection
- (2009) John McHutchison et al. GASTROENTEROLOGY
- Thiazolidinediones as Therapy for Endometriosis: A Case Series
- (2009) Molly B. Moravek et al. GYNECOLOGIC AND OBSTETRIC INVESTIGATION
- Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation
- (2009) H Kaneda et al. HEART
- Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
- (2009) Vlad Ratziu et al. HEPATOLOGY
- Primary biliary cirrhosis
- (2009) Keith D. Lindor et al. HEPATOLOGY
- A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes
- (2009) Tsutomu Takagi et al. JACC-Cardiovascular Interventions
- Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy
- (2009) John G Gerber et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- PPARδ is a fatty acid sensor that enhances mitochondrial oxidation in insulin-secreting cells and protects against fatty acid-induced dysfunction
- (2009) Kim Ravnskjaer et al. JOURNAL OF LIPID RESEARCH
- A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis
- (2009) Claudia C. Kaiser et al. JOURNAL OF NEUROIMMUNOLOGY
- PPAR- Contributes to the Anti-Inflammatory Activity of 17 -Estradiol
- (2009) C. Crisafulli et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose
- (2009) Eva M. Lonn et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study
- (2009) Robert R Henry et al. LANCET
- Myopathy with statin–fibrate combination therapy: clinical considerations
- (2009) Terry A. Jacobson Nature Reviews Endocrinology
- Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients
- (2009) S. J. Han et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- The effect of rosiglitazone on asymmetric dimethylarginine (ADMA) in critically ill patients
- (2009) M.C. Richir et al. PHARMACOLOGICAL RESEARCH
- PPARγ activation in adipocytes is sufficient for systemic insulin sensitization
- (2009) Shigeki Sugii et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PPAR blocks glucocorticoid receptor -mediated transactivation but cooperates with the activated glucocorticoid receptor for transrepression on NF- B
- (2009) N. Bougarne et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: A randomised controlled trial
- (2009) Duncan B. Richards et al. RESPIRATORY MEDICINE
- Results of Rosiglitazone Therapy in Patients with Thyroglobulin-Positive and Radioiodine-Negative Advanced Differentiated Thyroid Cancer
- (2009) Electron Kebebew et al. THYROID
- Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARα+γAgonists
- (2009) Martin B. Oleksiewicz et al. PPAR Research
- Cross-Talk between PPARs and the Partners of RXR: A Molecular Perspective
- (2009) Lap Shu Alan Chan et al. PPAR Research
- Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis
- (2008) R. IDILMAN et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)
- (2008) Robert Wilcox et al. AMERICAN HEART JOURNAL
- Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome
- (2008) L. W. Cho et al. CLINICAL ENDOCRINOLOGY
- Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride
- (2008) Cindy J Rubin et al. Diabetes & Vascular Disease Research
- A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
- (2008) C. Fernández-Miranda et al. DIGESTIVE AND LIVER DISEASE
- Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial
- (2008) Vlad Ratziu et al. GASTROENTEROLOGY
- Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
- (2008) Guruprasad P. Aithal et al. GASTROENTEROLOGY
- Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo-Controlled Trial
- (2008) James D. Lewis et al. GASTROENTEROLOGY
- The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study
- (2008) Shinji Iwasaki et al. HEPATOLOGY RESEARCH
- Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
- (2008) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Impaired Insulin Activation and Dephosphorylation of Glycogen Synthase in Skeletal Muscle of Women with Polycystic Ovary Syndrome Is Reversed by Pioglitazone Treatment
- (2008) Dorte Glintborg et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pioglitazone in chronic hepatitis C not responding to pegylated interferon-α and ribavirin
- (2008) Kathrin Overbeck et al. JOURNAL OF HEPATOLOGY
- PPARα activators upregulate eNOS activity and inhibit cytokine-induced NF-κB activation through AMP-activated protein kinase activation
- (2008) Toshie Okayasu et al. LIFE SCIENCES
- Distinct Functions of Vascular Endothelial and Smooth Muscle PPARγ in Regulation of Blood Pressure and Vascular Tone
- (2008) Ningning Wang et al. TOXICOLOGIC PATHOLOGY
- Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists
- (2007) Ramya Kapadia Frontiers in Bioscience-Landmark
- Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney Disease
- (2007) C. A. Schneider et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started